Opicinumab

DB14959Investigational

Opicinumab is under investigation in clinical trial NCT02641041 (Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BIIB033 in Healthy Japanese Participants).

Mechanism: Pharmacologically active on Leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 1
Curator reviewed
Code names: BIIB033

Resolves to

Compound

UNIIWX1WTN0Y15CAS1422268-07-2

Targets

Q96FE5LINGO1

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

381Drug interactionsStructured to mechanism, not free text

8Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Opicinumab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account